Media – Abzena


Abzena Annual Report 2016

The Company’s Annual Report for the year ended 31 March 2016 was released on 15 June 2016



World ADC San Diego

20 September 2017

Widen the Therapeutic Index of Your ADC Program World ADC San Diego is the definitive industry forum for accelerating the[...] Read more

American Biomanufacturing Summit

23 May 2017

Abzena is attending The American Biomanufacturing Summit is one of the most senior-level conferences and networking[...] Read more


A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead

Fungal ribotoxins that block protein synthesis can be useful warheads in the context of a targeted immunotoxin. α-Sarcin[...] Read more


‘Abzena inside’ product for neurodegenerative conditions moves into Phase II trial

Cambridge, UK, 6 March 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group[...] Read more

Abzena plc – Partner Halozyme to present poster at AACR

Cambridge, UK, 3 March 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group[...] Read more


We’re changing the way we brand our businesses

To provide our Partners with a single identity for the services and technologies offered across Antitope, PacificGMP,[...] Read more

Interested in our services? Get In Touch